company background image
SOPH

SOPHiA GENETICS NasdaqGS:SOPH Stock Report

Last Price

US$3.23

Market Cap

US$206.4m

7D

31.3%

1Y

n/a

Updated

26 Jun, 2022

Data

Company Financials +
SOPH fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

SOPH Stock Overview

SOPHiA GENETICS SA operates as a healthcare technology company.

SOPHiA GENETICS Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for SOPHiA GENETICS
Historical stock prices
Current Share PriceUS$3.23
52 Week HighUS$19.80
52 Week LowUS$2.16
Beta0
1 Month Change-24.00%
3 Month Change-56.17%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-80.73%

Recent News & Updates

Shareholder Returns

SOPHUS Healthcare ServicesUS Market
7D31.3%10.1%6.6%
1Yn/a-37.9%-18.4%

Return vs Industry: Insufficient data to determine how SOPH performed against the US Healthcare Services industry.

Return vs Market: Insufficient data to determine how SOPH performed against the US Market.

Price Volatility

Is SOPH's price volatile compared to industry and market?
SOPH volatility
SOPH Average Weekly Movement14.3%
Healthcare Services Industry Average Movement13.3%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: SOPH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: SOPH's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2011518Jurgi Camblonghttps://www.sophiagenetics.com

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide.

SOPHiA GENETICS Fundamentals Summary

How do SOPHiA GENETICS's earnings and revenue compare to its market cap?
SOPH fundamental statistics
Market CapUS$206.45m
Earnings (TTM)-US$86.49m
Revenue (TTM)US$42.34m

4.9x

P/S Ratio

-2.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SOPH income statement (TTM)
RevenueUS$42.34m
Cost of RevenueUS$16.02m
Gross ProfitUS$26.31m
Other ExpensesUS$112.81m
Earnings-US$86.49m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.35
Gross Margin62.16%
Net Profit Margin-204.31%
Debt/Equity Ratio0%

How did SOPH perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is SOPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SOPH?

Other financial metrics that can be useful for relative valuation.

SOPH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does SOPH's PS Ratio compare to its peers?

SOPH PS Ratio vs Peers
The above table shows the PS ratio for SOPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average28.4x

Price-To-Sales vs Peers: SOPH is good value based on its Price-To-Sales Ratio (4.9x) compared to the peer average (28.4x).


Price to Earnings Ratio vs Industry

How does SOPH's PE Ratio compare vs other companies in the U.S. Healthcare Services Industry?

Price-To-Sales vs Industry: SOPH is expensive based on its Price-To-Sales Ratio (4.9x) compared to the US Healthcare Services industry average (3.4x)


Price to Sales Ratio vs Fair Ratio

What is SOPH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SOPH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.9x
Fair PS Ratio6.2x

Price-To-Sales vs Fair Ratio: SOPH is good value based on its Price-To-Sales Ratio (4.9x) compared to the estimated Fair Price-To-Sales Ratio (6.2x).


Share Price vs Fair Value

What is the Fair Price of SOPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SOPH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SOPH's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SOPH's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is SOPHiA GENETICS forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


0.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SOPH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SOPH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SOPH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SOPH's revenue (29.8% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: SOPH's revenue (29.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SOPH is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has SOPHiA GENETICS performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-108.6%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: SOPH is currently unprofitable.

Growing Profit Margin: SOPH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if SOPH's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare SOPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SOPH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.7%).


Return on Equity

High ROE: SOPH has a negative Return on Equity (-34.34%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is SOPHiA GENETICS's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SOPH's short term assets ($259.9M) exceed its short term liabilities ($30.1M).

Long Term Liabilities: SOPH's short term assets ($259.9M) exceed its long term liabilities ($15.5M).


Debt to Equity History and Analysis

Debt Level: SOPH is debt free.

Reducing Debt: SOPH had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SOPH has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: SOPH has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 35.5% each year


Discover healthy companies

Dividend

What is SOPHiA GENETICS current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SOPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SOPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SOPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SOPH's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SOPH has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Jurgi Camblong (42 yo)

11.25yrs

Tenure

Dr. Jurgi Camblong, Ph D., M.B.A., serves as Chief Executive Officer and Director of SOPHiA GENETICS SA since March 2011. Dr. Camblong Co-founded SOPHiA GENETICS SA since March 2011.In 2010, Dr. Camblong...


Leadership Team

Experienced Management: SOPH's management team is considered experienced (2.2 years average tenure).


Board Members

Experienced Board: SOPH's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: SOPH only recently listed within the past 12 months.


Top Shareholders

Company Information

SOPHiA GENETICS SA's employee growth, exchange listings and data sources


Key Information

  • Name: SOPHiA GENETICS SA
  • Ticker: SOPH
  • Exchange: NasdaqGS
  • Founded: 2011
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Implied Market Cap: US$206.446m
  • Shares outstanding: 63.92m
  • Website: https://www.sophiagenetics.com

Number of Employees


Location

  • SOPHiA GENETICS SA
  • Rue du Centre 172
  • Saint-Sulpice
  • Vaud
  • 1025
  • Switzerland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.